A Phase 2 interventional study of Bendavia (MTP-131) and Placebo in Reperfusion Injury and STEMI, sponsored by Stealth BioTherapeutics Inc.. Completed at 30 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-06-11.
Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide (also known as MTP-131, or Bendavia) on a background of standard-of-care therapy for reduction of reperfusion injury in patients with first time acute, anterior wall ST-segment elevation myocardial infarction (STEMI).
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide on a background of standard-of-care therapy for reduction of reperfusion injury in patients with first time acute, anterior wall STEMI.
Patients were randomized to receive either an infusion of elamipretide at 0.05 mg/kg/hr or an identically appearing placebo administered as an IV infusion at 60 mL/hr. The infusion began at least 15 minutes but no more than 1 hour prior to the anticipated reperfusion event and continued through approximately 1 hour following re-establishment of blood flow through the culprit vessel.
The reduction of reperfusion injury, or infarct size, was estimated using the area under the curve (AUC) of the serum creatine kinase (CK) isoenzyme, as well as using magnetic resonance imaging (MRI) performed on the Day 4±1 and on Day 30±7 (both MRI assessments measured infarct size and the ratio of infarct size to myocardial mass). The analyses of cardiac MRI data were performed for both the primary endpoint population and also in all patients who had adequate Day 4/Day 30 cardiac MRI studies.
After completion of the percutaneous coronary intervention (PCI) and stenting, patients received standard medical treatment.
260 studies on the registry are indexed under Reperfusion Injury; 43 are open to participants now.
This study's enrollment of 300 is above the median of 60 across 212 interventional studies indexed under Reperfusion Injury.
Browse Reperfusion Injury studies →Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bendavia™ administered intravenously at 0.05 mg/kg/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
Drug: Bendavia (MTP-131)
Placebo administered intravenously at 60 mL/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
Drug: Placebo
0.05 mg/kg/hr
Also known as: MTP-131, Elamipretide
Identically appearing placebo
Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB)
Infarct size as measured by the AUC of serum CK-MB at 24 and 72 hours post-PCI
Time frame: The initial 24 and 72 hours post-percutaneous coronary intervention (PCI)
AUC of Troponin 1 Enzyme
Infarct size as calculated by the AUC of Troponin I Enzyme over the initial 24 and 72 hours post-PCI
Time frame: Initial 24 and 72 hours post-PCI
Ratio of Volume of Infarcted Myocardium to Left Ventricular Mass
Cardiac infarct size calculated as the ratio of volume of infarcted myocardium to left ventricular mass at Day 30 as measured by MRI.
Time frame: Day 30 + 7
Thrombosis in Myocardial Infarction (TIMI) Perfusion Grade Flow at Completion of PCI
TIMI perfusion grade flow at completion of PCI will be categorized as 0,1, or 1.5, 2 or 2.5, 3, and treated as ordinal data, where higher score means better perfusion and lower score means worse perfusion and worse outcome.
Time frame: Initiation to Completion of PCI, no longer than 4 hours
Corrected TIMI Frame Count
Corrected TIMI Frame Count at Completion of PCI as captured by angiogram and analyzed as a continuous variable.
Time frame: Completion of PCI, no longer than 4 hours
ST-Segmented Elevation From Pre-PCI to 24 Hours Post-PCI and Presence of ST-Segmented Resolution
ST-Segmented Elevation from pre-PCI to 24 hours post-PCI and Presence of ST-Segmented Resolution by ECG
Time frame: pre-PCI to 24 hours post-PCI
Change in Serum Creatinine From Baseline
Change in serum creatinine, from baseline (prior to study drug administration) to Day 30 +7 post-PCI
Time frame: Day 30 +7
Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline
Change in eGFR from baseline (prior to study drug administration) to Day 30 +7 post-PCI
Time frame: Day 30 +/- 7
Cystatin C Change From Baseline
Change in Cystatin C from baseline (prior to study drug administration) to Day 30 +7 post-PCI
Time frame: Day 30 + 7
Blood Urea Nitrogen (BUN) Change From Baseline
Blood Urea Nitrogen (BUN) Change from baseline (prior to study drug administration) to Day 30 + 7 post-PCI
Time frame: Baseline to Day 30
Number and Percent of Grade 1 Episode of Contrast-Induced Nephropathy Post-PCI
Number of Participants with Grade 1 Episode of Contrast-Induced Nephropathy within 48 hours of initial PCI or MRI, based on lab data.
Time frame: Baseline to 48 hours post PCI or MRI
Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation
Number and percent of participants with Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation Requiring Medical Intervention
Time frame: Baseline up to 1 hour post-PCI
Immediate Myocardial Complications: Mechanical Complications
Number and Percent of Participants with Immediate Myocardial Complications: Mechanical Complications: (Free wall Rupture, Ventricular Septal Defect, Ischemic Mitral Regurgitation)
Time frame: Baseline up to 1 hour post-PCI
Emergency Use of Medications During PCI Procedure
Emergency Use of Nitroprusside, Calcium Channel Blocker, Adenosine Administration During the PCI Procedure
Time frame: Initiation to Completion of PCI, no longer than 4 hours
ProB-type Natriuretic Peptide (NT-proBNP) Change From Baseline to Day 30
NT-proBNP: Change from baseline to Day 30 +7 (Laboratory marker for chronic heart failure (CHF) and systemic inflammation.)
Time frame: Baseline to Day 30
High Sensitivity C-Reactive Protein (hsCRP): Change From Baseline to Day 30
High Sensitivity C-Reactive Protein (hsCRP): Change from baseline to Day 30 +7 (Laboratory Marker for CHF and Systemic Inflammation)
Time frame: Baseline to Day 30
Left Ventricular (LV) Ejection Fraction (%)
Difference in Left Ventricular (LV) Ejection Fraction (%) from Day 4 To Day 30
Time frame: Day 4 to Day 30
Difference Between Left Ventricular End Diastolic Volume, Corrected
Difference between Left Ventricular End Diastolic Volume Corrected for Body Surface Area between Day 4 and Day 30
Time frame: Day 4 and Day 30
Difference Between Left Ventricular End Systolic Volume, Corrected
Difference between Left Ventricular End Systolic Volume Corrected for Body Surface Area from Day 4 and Day 30
Time frame: Day 4 and Day 30
Chronic Heart Failure
Number and Percentage of Patients with Clinical Events: Chronic Heart Failure beginning within 24 hours after PCI but within the duration of the index hospitalization (Subjects with CHF started within 24 hours after the last balloon deflation while the patient was still in the hospital {including patients who had missing discharge date}).
Time frame: Within 24 hours after PCI
| Milestone | Bendavia™ | Placebo |
|---|---|---|
| Started | 152 | 148 |
| Completed | 120 | 123 |
| Not completed | 32 | 25 |
| Withdrew: Adverse event | 7 | 2 |
| Withdrew: Death | 3 | 1 |
| Withdrew: Lost to follow-up | 8 | 7 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Technical issues | 1 | 0 |
| Withdrew: Withdrawal by subject | 12 | 11 |
| Withdrew: Infarct, comorbidity, pt refusal of exam | 0 | 3 |
Infarct size as measured by the AUC of serum CK-MB at 24 and 72 hours post-PCI
| ng*hr/mL | Bendavia™ | Placebo |
|---|---|---|
| 72 Hours | 6582.0 ± 3270.6 | 6738.3 ± 3775.4 |
| 24 Hours | 5252.2 ± 2667.9 | 5471.9 ± 3270.7 |
Infarct size as calculated by the AUC of Troponin I Enzyme over the initial 24 and 72 hours post-PCI
| ng*hr/mL | Bendavia™ | Placebo |
|---|---|---|
| 72 Hours | 5422.9 ± 3430.9 | 4647.2 ± 2834.7 |
| 24 Hours | 3301.4 ± 2192.9 | 2850.4 ± 1640.6 |
Cardiac infarct size calculated as the ratio of volume of infarcted myocardium to left ventricular mass at Day 30 as measured by MRI.
| ratio | Bendavia™ | Placebo |
|---|---|---|
| Ratio of Volume of Infarcted Myocardium to Left Ventricular Mass | 242.3 ± 87.3 | 225.2 ± 90.70 |
TIMI perfusion grade flow at completion of PCI will be categorized as 0,1, or 1.5, 2 or 2.5, 3, and treated as ordinal data, where higher score means better perfusion and lower score means worse perfusion and worse outcome.
| Participants | Bendavia™ | Placebo |
|---|---|---|
| Flow Grade 0 | 0 | 0 |
| Flow Grade 1 or 1.5 | 0 | 0 |
| Flow Grade 2 or 2.5 | 6 | 7 |
| Flow Grade 3 | 52 | 53 |
Corrected TIMI Frame Count at Completion of PCI as captured by angiogram and analyzed as a continuous variable.
| corrected frame count | Bendavia™ | Placebo |
|---|---|---|
| Corrected TIMI Frame Count | 79.7 ± 122.8 | 166.0 ± 286.8 |
ST-Segmented Elevation from pre-PCI to 24 hours post-PCI and Presence of ST-Segmented Resolution by ECG
| Participants | Bendavia™ | Placebo |
|---|---|---|
| Complete (>=70% resolution) | 30 | 29 |
| Partial (<70% resolution) | 22 | 21 |
| None (<30% resolution) | 4 | 7 |
Change in serum creatinine, from baseline (prior to study drug administration) to Day 30 +7 post-PCI
| umol/L | Bendavia™ | Placebo |
|---|---|---|
| Change in Serum Creatinine From Baseline | 10.55 ± 17.642 | 88.04 ± 22.462 |
Change in eGFR from baseline (prior to study drug administration) to Day 30 +7 post-PCI
| mL/min/SSA | Bendavia™ | Placebo |
|---|---|---|
| Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline | -12.33 ± 18.873 | -8.94 ± 14.242 |
Change in Cystatin C from baseline (prior to study drug administration) to Day 30 +7 post-PCI
| mg/L | Bendavia™ | Placebo |
|---|---|---|
| Cystatin C Change From Baseline | 0.19 ± 0.341 | 0.19 ± 0.226 |
Blood Urea Nitrogen (BUN) Change from baseline (prior to study drug administration) to Day 30 + 7 post-PCI
| mmol/L | Bendavia™ | Placebo |
|---|---|---|
| Blood Urea Nitrogen (BUN) Change From Baseline | -0.13 ± 1.603 | 0.13 ± 2.207 |
Number of Participants with Grade 1 Episode of Contrast-Induced Nephropathy within 48 hours of initial PCI or MRI, based on lab data.
| Participants | Bendavia™ | Placebo |
|---|---|---|
| Yes | 17 | 11 |
| No | 41 | 49 |
Number and percent of participants with Immediate Myocardial Complications: Ventricular Tachycardia or Fibrillation Requiring Medical Intervention
| Participants | Bendavia™ | Placebo |
|---|---|---|
| Yes | 2 | 3 |
| No | 56 | 57 |
Number and Percent of Participants with Immediate Myocardial Complications: Mechanical Complications: (Free wall Rupture, Ventricular Septal Defect, Ischemic Mitral Regurgitation)
| Participants | Bendavia™ | Placebo |
|---|---|---|
| Immediate Myocardial Complications: Mechanical Complications | 1 | 0 |
Emergency Use of Nitroprusside, Calcium Channel Blocker, Adenosine Administration During the PCI Procedure
| Participants | Bendavia™ | Placebo |
|---|---|---|
| Yes | 5 | 3 |
| No | 53 | 57 |
NT-proBNP: Change from baseline to Day 30 +7 (Laboratory marker for chronic heart failure (CHF) and systemic inflammation.)
| pg/mL | Bendavia™ | Placebo |
|---|---|---|
| ProB-type Natriuretic Peptide (NT-proBNP) Change From Baseline to Day 30 | 1828.45 ± 3427.408 | 1582.67 ± 1502.985 |
High Sensitivity C-Reactive Protein (hsCRP): Change from baseline to Day 30 +7 (Laboratory Marker for CHF and Systemic Inflammation)
| mg/L | Bendavia™ | Placebo |
|---|---|---|
| High Sensitivity C-Reactive Protein (hsCRP): Change From Baseline to Day 30 | -1.03 ± 7.072 | -0.91 ± 7.024 |
Difference in Left Ventricular (LV) Ejection Fraction (%) from Day 4 To Day 30
| percentage of blood volume | Bendavia™ | Placebo |
|---|---|---|
| Left Ventricular (LV) Ejection Fraction (%) | 2.1 ± 6.4 | 2.5 ± 8.3 |
Difference between Left Ventricular End Diastolic Volume Corrected for Body Surface Area between Day 4 and Day 30
| mL/m2 | Bendavia™ | Placebo |
|---|---|---|
| Difference Between Left Ventricular End Diastolic Volume, Corrected | 8.6 ± 12.6 | 6.2 ± 15.1 |
Difference between Left Ventricular End Systolic Volume Corrected for Body Surface Area from Day 4 and Day 30
| mL/m² | Bendavia™ | Placebo |
|---|---|---|
| Difference Between Left Ventricular End Systolic Volume, Corrected | 2.7 ± 8.0 | 1.5 ± 12.5 |
Number and Percentage of Patients with Clinical Events: Chronic Heart Failure beginning within 24 hours after PCI but within the duration of the index hospitalization (Subjects with CHF started within 24 hours after the last balloon deflation while the patient was still in the hospital {including patients who had missing discharge date}).
| Participants | Bendavia™ | Placebo |
|---|---|---|
| Yes | 8 | 15 |
| No | 50 | 45 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bendavia™ | 10/150 (6.7%) | 20/150 (13.3%) | 112/150 (74.7%) |
| Placebo | 3/147 (2%) | 14/147 (9.5%) | 106/147 (72.1%) |
| Event | Bendavia™ | Placebo |
|---|---|---|
| Cardiogenic ShockCardiac disorders | 4/150 | 0/147 |
| Acute Myocardial InfarctionCardiac disorders | 1/150 | 2/147 |
| PneumoniaInfections and infestations | 2/150 | 2/147 |
| Cardiac FailureCardiac disorders | 0/150 | 2/147 |
| Thrombosis in DeviceGeneral disorders | 2/150 | 0/147 |
| Ventricular FibrillationCardiac disorders | 1/150 | 1/147 |
| Cardiac tamponadeCardiac disorders | 0/150 | 1/147 |
| Cardiac ArrestCardiac disorders | 0/150 | 1/147 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 0/150 | 1/147 |
| Pancreatic NeoplasmsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/150 | 1/147 |
| Event | Bendavia™ | Placebo |
|---|---|---|
| HypercholesterolaemiaMetabolism and nutrition disorders | 30/150 | 19/147 |
| Cardiac FailureCardiac disorders | 28/150 | 29/147 |
| HypokalaemiaMetabolism and nutrition disorders | 27/150 | 27/147 |
| AnxietyPsychiatric disorders | 9/150 | 14/147 |
| Diabetes mellitusMetabolism and nutrition disorders | 12/150 | 7/147 |
| Angina PectorisCardiac disorders | 11/150 | 6/147 |
| HypertensionVascular disorders | 11/150 | 9/147 |
| Intracardiac ThrombusCardiac disorders | 9/150 | 10/147 |
| PyrexiaGeneral disorders | 5/150 | 9/147 |
| HyperlipidaemiaMetabolism and nutrition disorders | 6/150 | 9/147 |
300 patients were randomized and only 297 were included in the Safety Population, which consists of all patients who took any fraction of study drug using actual treatment received. If patient was randomized to placebo and received elamipretide, patient's actual treatment was recognized as elamipretide (and vice versa).
| Age, Continuous(years) | Bendavia™ | Placebo | Total |
|---|---|---|---|
| Mean | 60.7 ± 11 | 60.1 ± 10.6 | 60.4 ± 10.8 |
| Sex: Female, Male(Participants) | Bendavia™ | Placebo | Total |
|---|---|---|---|
| Female | 45 | 28 | 73 |
| Male | 105 | 119 | 224 |
| Race (NIH/OMB)(Participants) | Bendavia™ | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 0 | 0 | 0 |
| White | 150 | 146 | 296 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Apr 2012, a primary completion of Nov 2014 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2020, 5 years 7 months after primary completion. A results delay was requested in Nov 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →